N-Zyme Biomedical is a clinical-stage biotechnology company developing first-in-class therapies targeting pepsin, a key driver of tissue damage in reflux disease. The company's lead program is currently being evaluated in Phase 2 clinical trials for laryngopharyngeal reflux (LPR), with additional development planned for patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD).

Key Contact